CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I-II Study of HER2 Vaccination With Poly(I) • Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01355393
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:25.172630+00:00
Published At: 2020-02-10T00:00:00+00:00
Record Updated At: 2020-02-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["HER2-positive Breast Cancer", "Male Breast Cancer", "Recurrent Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-02-10"
protocolSection.identificationModule.nctId: "NCT01355393"
protocolSection.identificationModule.officialTitle: "Phase I-II Study of HER2 Vaccination With Poly(I) \u2022 Poly(C12U) (Ampligen\u00ae) as an Adjuvant in Optimally Treated Breast Cancer Patients"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.